Insulin-like growth factor i improves height in growth hormone insensitivity: Two years’ results

M. B. Ranke, M. O. Savage, P. G. Chatelain, M. A. Preece, Ronald (Ron) Rosenfeld, W. F. Blum, P. Wilton

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Thirty-one patients with growth hormone insensitivity syndrome (GHIS) and 2 with GH gene deletion (age 11.2 (3.7–22.9) years; BA (GP) 8.2 years; height −6.5 ± 1.6 SDS) were recruited for the multicenter study. At birth, length was more retarded (−1.38 SDS) than weight (−0.56 SDS). The rhIGF-I dose was 40-120 μg/kg BW twice daily s.c. In 26 patients, first year HV increased from 3.9 ± 1.8 to 8.5 ± 2.1 cm/year (delta (d) HT SDS 0.8 ± 0.5). In 18 patients, second year HV was 6.4 ± 2.2 cm/year (dHT SDS 0.4 ± 0.5). There was normal progression of puberty. Mean progression of BA was 1.2 and 1.5 years/ year during the first and second year. There was no dose effect of IGF-I on growth. Weight-for-height index (WHI) and skinfold thickness were significantly correlated at start, 12 and 24 months (r = 0.83, 0.87 and 0.79). Changes in WHI were positively correlated with dHT SDS during the first and second year (r = 0.54, 0.56). Serum IGF-I rose, IGF-II decreased, and IGFBP-3 remained constant. Adverse events were (number of occasions): Headache (21) (early); hypoglycemia (13); papilloedema (1) (reversible); Bell’s palsy (1) (reversible); lipohypertrophy (7) (late); tonsillectomy/adenoidectomy (3) (late). The results show that there is effective long-term treatment of GHIS with systemically administered IGF-I and support the view that IGFBPs play an important role in the action of IGF-I.

Original languageEnglish (US)
Pages (from-to)253-264
Number of pages12
JournalHormone Research in Paediatrics
Volume44
Issue number6
DOIs
StatePublished - 1995

Fingerprint

Somatomedins
Insulin-Like Growth Factor I
Growth Hormone
Laron Syndrome
Weights and Measures
Bell Palsy
Adenoidectomy
Skinfold Thickness
Insulin-Like Growth Factor Binding Proteins
Papilledema
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor II
Tonsillectomy
Gene Deletion
Puberty
Hypoglycemia
Multicenter Studies
Headache
Parturition
Growth

Keywords

  • Growth hormone insensitivity
  • IGF-I
  • Therapy

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health

Cite this

Ranke, M. B., Savage, M. O., Chatelain, P. G., Preece, M. A., Rosenfeld, R. R., Blum, W. F., & Wilton, P. (1995). Insulin-like growth factor i improves height in growth hormone insensitivity: Two years’ results. Hormone Research in Paediatrics, 44(6), 253-264. https://doi.org/10.1159/000184637

Insulin-like growth factor i improves height in growth hormone insensitivity : Two years’ results. / Ranke, M. B.; Savage, M. O.; Chatelain, P. G.; Preece, M. A.; Rosenfeld, Ronald (Ron); Blum, W. F.; Wilton, P.

In: Hormone Research in Paediatrics, Vol. 44, No. 6, 1995, p. 253-264.

Research output: Contribution to journalArticle

Ranke, MB, Savage, MO, Chatelain, PG, Preece, MA, Rosenfeld, RR, Blum, WF & Wilton, P 1995, 'Insulin-like growth factor i improves height in growth hormone insensitivity: Two years’ results', Hormone Research in Paediatrics, vol. 44, no. 6, pp. 253-264. https://doi.org/10.1159/000184637
Ranke, M. B. ; Savage, M. O. ; Chatelain, P. G. ; Preece, M. A. ; Rosenfeld, Ronald (Ron) ; Blum, W. F. ; Wilton, P. / Insulin-like growth factor i improves height in growth hormone insensitivity : Two years’ results. In: Hormone Research in Paediatrics. 1995 ; Vol. 44, No. 6. pp. 253-264.
@article{232b1bd11a924f65887955e29fbd16c7,
title = "Insulin-like growth factor i improves height in growth hormone insensitivity: Two years’ results",
abstract = "Thirty-one patients with growth hormone insensitivity syndrome (GHIS) and 2 with GH gene deletion (age 11.2 (3.7–22.9) years; BA (GP) 8.2 years; height −6.5 ± 1.6 SDS) were recruited for the multicenter study. At birth, length was more retarded (−1.38 SDS) than weight (−0.56 SDS). The rhIGF-I dose was 40-120 μg/kg BW twice daily s.c. In 26 patients, first year HV increased from 3.9 ± 1.8 to 8.5 ± 2.1 cm/year (delta (d) HT SDS 0.8 ± 0.5). In 18 patients, second year HV was 6.4 ± 2.2 cm/year (dHT SDS 0.4 ± 0.5). There was normal progression of puberty. Mean progression of BA was 1.2 and 1.5 years/ year during the first and second year. There was no dose effect of IGF-I on growth. Weight-for-height index (WHI) and skinfold thickness were significantly correlated at start, 12 and 24 months (r = 0.83, 0.87 and 0.79). Changes in WHI were positively correlated with dHT SDS during the first and second year (r = 0.54, 0.56). Serum IGF-I rose, IGF-II decreased, and IGFBP-3 remained constant. Adverse events were (number of occasions): Headache (21) (early); hypoglycemia (13); papilloedema (1) (reversible); Bell’s palsy (1) (reversible); lipohypertrophy (7) (late); tonsillectomy/adenoidectomy (3) (late). The results show that there is effective long-term treatment of GHIS with systemically administered IGF-I and support the view that IGFBPs play an important role in the action of IGF-I.",
keywords = "Growth hormone insensitivity, IGF-I, Therapy",
author = "Ranke, {M. B.} and Savage, {M. O.} and Chatelain, {P. G.} and Preece, {M. A.} and Rosenfeld, {Ronald (Ron)} and Blum, {W. F.} and P. Wilton",
year = "1995",
doi = "10.1159/000184637",
language = "English (US)",
volume = "44",
pages = "253--264",
journal = "Hormone Research in Paediatrics",
issn = "1663-2818",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Insulin-like growth factor i improves height in growth hormone insensitivity

T2 - Two years’ results

AU - Ranke, M. B.

AU - Savage, M. O.

AU - Chatelain, P. G.

AU - Preece, M. A.

AU - Rosenfeld, Ronald (Ron)

AU - Blum, W. F.

AU - Wilton, P.

PY - 1995

Y1 - 1995

N2 - Thirty-one patients with growth hormone insensitivity syndrome (GHIS) and 2 with GH gene deletion (age 11.2 (3.7–22.9) years; BA (GP) 8.2 years; height −6.5 ± 1.6 SDS) were recruited for the multicenter study. At birth, length was more retarded (−1.38 SDS) than weight (−0.56 SDS). The rhIGF-I dose was 40-120 μg/kg BW twice daily s.c. In 26 patients, first year HV increased from 3.9 ± 1.8 to 8.5 ± 2.1 cm/year (delta (d) HT SDS 0.8 ± 0.5). In 18 patients, second year HV was 6.4 ± 2.2 cm/year (dHT SDS 0.4 ± 0.5). There was normal progression of puberty. Mean progression of BA was 1.2 and 1.5 years/ year during the first and second year. There was no dose effect of IGF-I on growth. Weight-for-height index (WHI) and skinfold thickness were significantly correlated at start, 12 and 24 months (r = 0.83, 0.87 and 0.79). Changes in WHI were positively correlated with dHT SDS during the first and second year (r = 0.54, 0.56). Serum IGF-I rose, IGF-II decreased, and IGFBP-3 remained constant. Adverse events were (number of occasions): Headache (21) (early); hypoglycemia (13); papilloedema (1) (reversible); Bell’s palsy (1) (reversible); lipohypertrophy (7) (late); tonsillectomy/adenoidectomy (3) (late). The results show that there is effective long-term treatment of GHIS with systemically administered IGF-I and support the view that IGFBPs play an important role in the action of IGF-I.

AB - Thirty-one patients with growth hormone insensitivity syndrome (GHIS) and 2 with GH gene deletion (age 11.2 (3.7–22.9) years; BA (GP) 8.2 years; height −6.5 ± 1.6 SDS) were recruited for the multicenter study. At birth, length was more retarded (−1.38 SDS) than weight (−0.56 SDS). The rhIGF-I dose was 40-120 μg/kg BW twice daily s.c. In 26 patients, first year HV increased from 3.9 ± 1.8 to 8.5 ± 2.1 cm/year (delta (d) HT SDS 0.8 ± 0.5). In 18 patients, second year HV was 6.4 ± 2.2 cm/year (dHT SDS 0.4 ± 0.5). There was normal progression of puberty. Mean progression of BA was 1.2 and 1.5 years/ year during the first and second year. There was no dose effect of IGF-I on growth. Weight-for-height index (WHI) and skinfold thickness were significantly correlated at start, 12 and 24 months (r = 0.83, 0.87 and 0.79). Changes in WHI were positively correlated with dHT SDS during the first and second year (r = 0.54, 0.56). Serum IGF-I rose, IGF-II decreased, and IGFBP-3 remained constant. Adverse events were (number of occasions): Headache (21) (early); hypoglycemia (13); papilloedema (1) (reversible); Bell’s palsy (1) (reversible); lipohypertrophy (7) (late); tonsillectomy/adenoidectomy (3) (late). The results show that there is effective long-term treatment of GHIS with systemically administered IGF-I and support the view that IGFBPs play an important role in the action of IGF-I.

KW - Growth hormone insensitivity

KW - IGF-I

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0029619119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029619119&partnerID=8YFLogxK

U2 - 10.1159/000184637

DO - 10.1159/000184637

M3 - Article

C2 - 8808010

AN - SCOPUS:0029619119

VL - 44

SP - 253

EP - 264

JO - Hormone Research in Paediatrics

JF - Hormone Research in Paediatrics

SN - 1663-2818

IS - 6

ER -